MicroRNA-145: A promising biomarker for hepatocellular carcinoma (HCC)

Gene

Volumn 541, Issue 1, 2014, Pages 67-68

  Duan, Xianchun ^a   Hu, Jianpeng ^a   Wang, Yongzhong ^a   Gao, Jiarong ^a   Peng, Daiyin ^a   Xia, Lunzhu ^a  

^a ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Hepatocellular carcinoma; MiR 145

Indexed keywords

HISTONE DEACETYLASE 2; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MICRORNA 122; MICRORNA 145; MICRORNA 146A; MICRORNA 200C; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 31; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

APOPTOSIS; BILE DUCT CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMING UNIT; DOWN REGULATION; HUMAN; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

HEPATOCELLULAR CARCINOMA; MIR-145;

CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS;

EID: 84896547194     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.03.018     Document Type: Letter

References (8)

1. Gao P., Wong C.C., Tung E.K., Lee J.M., Wong C.M., Ng I.O. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. Journal of Hepatology 2011, 54:1177-1184.
2. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., Calin G.A., Giovannini C., Ferrazzi E., Grazi G.L., Croce C.M., Bolondi L., Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Research 2007, 67:6092-6099.
3. Karakatsanis A., Papaconstantinou I., Gazouli M., Lyberopoulou A., Polymeneas G., Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Molecular Carcinogenesis 2013, 52:297-303.
4. Law P.T., Ching A.K., Chan A.W., Wong Q.W., Wong C.K., To K.F., Wong N. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012, 33:1134-1141.
5. Noh J.H., Chang Y.G., Kim M.G., Jung K.H., Kim J.K., Bae H.J., Eun J.W., Shen Q., Kim S.J., Kwon S.H., Park W.S., Lee J.Y., Nam S.W. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Letters 2013, 335:455-462.
6. Wang L., Guo Z.Y., Zhang R., Xin B., Chen R., Zhao J., Wang T., Wen W.H., Jia L.T., Yao L.B., Yang A.G. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis 2013, 34:1773-1781.
7. Wang X.J., Feng C.W., Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Molecular and Cellular Biochemistry 2013, 380:57-66.
8. Yang X.W., Zhang L.J., Huang X.H., Chen L.Z., Su Q., Zeng W.T., Li W., Wang Q. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatology Research 2013, 10.1111/hepr.12152.